Morristown

Tidal Wave Auto Spa Celebrates New Opening in Cookeville, TN With Free Washes

Retrieved on: 
Tuesday, January 10, 2023
UV, Holiday, Morristown, Happiness, Wash, School, Renewable energy, Online shopping, Tidal wave

To celebrate its grand opening, the new Cookeville location is offering free washes from 9:00 a.m. to 6:00 p.m. through Sunday, Jan. 15.

Key Points: 
  • To celebrate its grand opening, the new Cookeville location is offering free washes from 9:00 a.m. to 6:00 p.m. through Sunday, Jan. 15.
  • Tidal Wave Auto Spa was founded by Scott and Hope Blackstock in 1999.
  • An ideal choice for the holidays, birthdays or celebrations, a Tidal Wave Auto Spa gift card can fit any gift-giving need.
  • For more information about how to partner with Tidal Wave Auto Spa for your next fundraiser, please visit http://www.tidalwaveautospa.com/fundraising .

RIA M&A in Focus: Ahead of Annual Gladstone M&A Conference, Gladstone Associates Highlights 2 Recent Transactions

Retrieved on: 
Tuesday, May 3, 2022
Consulting, Professional Services, Finance, RIA, LLC, COVID, Environment, Industry, RIAS, Fox Business, Morristown, Conference, Solution, CEO, Heart, Acquisition, William Ewart Gladstone, Financial adviser

The environment for RIA firm transactions remains robust and the outlook for M&A will be in focus on May 3rd & 4th at the annual Gladstone M&A Conference being held in Philadelphia.

Key Points: 
  • The environment for RIA firm transactions remains robust and the outlook for M&A will be in focus on May 3rd & 4th at the annual Gladstone M&A Conference being held in Philadelphia.
  • As the conference organizer, Gladstone Associates is at the heart of RIA deal-making.
  • The firm recently served in a buy-side advisory capacity for both Simon Quick Advisors and Cerity Partners in their recently announced acquisitions.
  • Established in 2006, Gladstone Group Inc. is a nationally recognized, specialized company offering M&A advisory for RIAs (through Gladstone Associates, LLC) and executive search (via D.A.

BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

Retrieved on: 
Friday, October 29, 2021
Death, Infection, Kidney, Lists of diseases, Disease, IP, Inflammation, Patient, Degenerative disease, Manifest and latent functions and dysfunctions, Multiple sclerosis, Telephone numbers in South Africa, Risk, ICU, Conference, MACRO, End organ damage, Steroid, COVID-19, Investor relations, COO, Gold, King Juan Carlos University, Survivor, Therapy, Mortality, Human Protein Atlas, GLOBE, Gelsolin (cellular), Pharmaceutical industry, Vaccine

Co-founders Valerie Ceva, COO, and Steven Cordovano, Vice President of Investor Relations, will present Conquering Pneumonia and Systemic Inflammation with a Human Protein, and highlight gelsolin, BioAegis novel host-directed treatment.

Key Points: 
  • Co-founders Valerie Ceva, COO, and Steven Cordovano, Vice President of Investor Relations, will present Conquering Pneumonia and Systemic Inflammation with a Human Protein, and highlight gelsolin, BioAegis novel host-directed treatment.
  • Supplementing human gelsolin with a recombinant form is a host-directed approach to treating inflammatory and infectious diseases.
  • Gelsolin, a naturally occurring human protein that is abundant in healthy individuals, is a key component of the bodys innate immune system.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response

Retrieved on: 
Tuesday, September 28, 2021
Therapy, Recombinant, Degenerative disease, Steroid, Infection, Inflammation, Immunity, Patient, Population, Bacteria, IP, Journal, Injury, End organ damage, Kidney, Quorum sensing, CEO, Death, Phenotype, Disease, Risk, Programmed cell death protein 1, Saipan, Science, COVID-19, Pneumonia, Lists of diseases, Telephone numbers in South Africa, Cell, California Uninsured Patient Hospital Pricing Litigation, NORTH, Multiple sclerosis, GLOBE, Pharmaceutical industry, Vaccine

NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown role of gelsolin in a signaling system in macrophages was published in the Journal of Immunology.

Key Points: 
  • The paper, Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in Macrophages , was recently published in the Journal of Immunology.
  • The study shows that plasma gelsolin (pGSN) controls this process by regulating the expression of a protein known as Programmed Cell Death 4 (PCD4).
  • Gelsolin, a naturally occurring human protein that is abundant in healthy individuals, is a key component of the bodys innate immune system.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

Retrieved on: 
Friday, August 27, 2021
Company, Hypotension, Blood pressure, COVID, Pneumonia, Trial of the century, GLOBE, Recombinant, Degenerative disease, Hospital, California Uninsured Patient Hospital Pricing Litigation, Health, Death, Therapy, NORTH, Inflammation, Infection, Safety, Kidney, Disease, Patient, Lists of diseases, Telephone numbers in South Africa, COVID-19, Recombinant human parathyroid hormone, IP, Multiple sclerosis, Pharmaceutical industry, Vaccine

NORTH BRUNSWICK, N.J., Aug. 27, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a case study, Recombinant Human Plasma Gelsolin (rhu-pGSN) in a Patient Hospitalized with Critical COVID-19 Pneumonia, was published in Clinical Infection in Practice.

Key Points: 
  • This compassionate-use case paper is intended to introduce clinicians to BioAegis novel host-based therapeutic, rhu-pGSN, under development for critical COVID-19 pneumonia as well as for other serious infectious and noninfectious diseases.
  • The patient became hypotensive, requiring pressors to keep her blood pressure up for 36 hours.
  • Study co-author and BioAegis Chief Medical Officer, Dr. Mark DiNubile, remarked,
    While a single case study does not prove efficacy of our treatment, it was gratifying to observe a rapid and complete recovery of a patient with critical COVID pneumonia.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Proteins, Biology, Life sciences, Biotechnology, Molecular biology, Plasma gelsolin, Molecular genetics, Recombinant DNA, Gelsolin, Recombinant

The DRIVe (BARDAs Division of Research, Innovation and Ventures) Solving Sepsis initiative seeks innovative host-based approaches for the development of diagnostics, devices and therapeutics.

Key Points: 
  • The DRIVe (BARDAs Division of Research, Innovation and Ventures) Solving Sepsis initiative seeks innovative host-based approaches for the development of diagnostics, devices and therapeutics.
  • BioAegis offers a novel recombinant protein therapy with the potential to broadly treat inflammatory disorders, like sepsis, that can arise from injury or infection.
  • The product is the recombinant form of a naturally occurring human host protein with a benign safety profile in clinical trials.
  • BioAegis platform is built upon the recombinant form of plasma gelsolin, a highly conserved abundant human protein in healthy individuals.

JCP&L President Jim Fakult Elected Chairman of N.J. Chamber of Commerce

Retrieved on: 
Thursday, June 10, 2021
Regions of the United States, Geography of the United States, Corporate crime, FirstEnergy, Jersey Central, NEW JERSEY, Morristown, PNC Financial Services

MORRISTOWN, N.J., June 10, 2021 /PRNewswire/ --Jim Fakult, president of Jersey Central Power and Light (JCP&L), a subsidiary of FirstEnergy Corp. (NYSE: FE), has been elected chairman of the New Jersey Chamber of Commerce.

Key Points: 
  • MORRISTOWN, N.J., June 10, 2021 /PRNewswire/ --Jim Fakult, president of Jersey Central Power and Light (JCP&L), a subsidiary of FirstEnergy Corp. (NYSE: FE), has been elected chairman of the New Jersey Chamber of Commerce.
  • Fakult, who has spent the past 33 years with FirstEnergy, has led JCP&L since 2013, the same year he joined the Chamber Board of Directors.
  • Fakult succeeds Linda Bowden, who is retiring from her position as New Jersey Regional President at PNC Bank.
  • "Jim has long been a powerful supporter of the New Jersey Chamber, the business community and the state of New Jersey.

EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year® 2021 New Jersey Award Finalist

Retrieved on: 
Friday, June 4, 2021
Business, Articles, Economy, Ernst & Young, Entrepreneurship

Dr. Levinson has founded two New Jersey biotech companies in partnership with scientific and business founders and is passionately committed to developing unique products to meet patient needs.

Key Points: 
  • Dr. Levinson has founded two New Jersey biotech companies in partnership with scientific and business founders and is passionately committed to developing unique products to meet patient needs.
  • Dr. Levinson was recently elected to the Board of BioNJ , the NJ biotech trade association.
  • Entrepreneur Of The Year is one of the preeminent competitive award programs for entrepreneurs and leaders of high-growth companies.
  • EY Private teams offer distinct insights born from the long EY history of working with business owners and entrepreneurs.

BCN Teams with Sandler Partners to Expand Channel Reach

Retrieved on: 
Tuesday, May 4, 2021
Magazines, Bi Community News, Zines, Periodicals

"BCN consistently delivers on their commitments and brings the kind of accessibility and responsiveness our partners want and deserve.

Key Points: 
  • "BCN consistently delivers on their commitments and brings the kind of accessibility and responsiveness our partners want and deserve.
  • "\n\xe2\x80\x9cBCN is honored to be a part of Sandler Partner\xe2\x80\x99s robust portfolio of market-leading solutions.
  • In addition, BCN provides customers with one monthly invoice for all services and a state-of-the-art portal to manage their BCN business.\nFor 27 years, BCN has delivered best-in-class solutions domestically and internationally to business customers.
  • In 2020, Sandler Partners was included on the Inc. 5000 list of America\xe2\x80\x99s Fastest-Growing Private Companies for the 11th straight year.

BCN Welcomes Vern Jaques as Partner Sales Director

Retrieved on: 
Monday, April 12, 2021

b'Morristown, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- BCN , a New Jersey-based communications technology solution provider focused on multi-location businesses welcomes Vern Jaques to the company as a Partner Sales Director.

Key Points: 
  • b'Morristown, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- BCN , a New Jersey-based communications technology solution provider focused on multi-location businesses welcomes Vern Jaques to the company as a Partner Sales Director.
  • Located in Denver, Colorado, Vern will focus on servicing and growing our channel sales partner relationships in the West region.
  • The BCN portfolio includes a full complement of emerging and traditional services and technology options.
  • In addition, BCN provides customers with one monthly invoice for all services and a state-of-the-art portal to manage their BCN business.\nFor over 27 years, BCN has delivered best-in-class solutions domestically and internationally to business customers.